Artal Group’s United Therapeutics UTHR Stock Holding History

Artal Group’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,971	Closed	-$656K	–	119
2023 Q2	$656K	Sell	2,971 -310	-9%	-$68.7K	0.02%	97
2023 Q1	$735K	Buy	+3,281	New	+$809K	0.04%	98

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Artal Group's UTHR Position: Q3 2023 in Review

Artal Group sold out of United Therapeutics (UTHR) in Q3 2023, closing a stake of 2,971 shares — an estimated $656K sold.

Artal Group first reported a position in UTHR in Q1 2023 and held it in 2 quarters. The position peaked at $735K in Q1 2023. 508 funds tracked by Wall St. Rank hold UTHR as of Q3 2023.

Artal Group reported no remaining United Therapeutics position as of Q3 2023 after selling out during the quarter.
Artal Group sold 2,971 United Therapeutics shares in Q3 2023, an estimated $656K.
Artal Group first reported a position in United Therapeutics in Q1 2023 and held it in 2 quarters.
Artal Group's United Therapeutics position peaked at $735K in Q1 2023.
508 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2023.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.